Sponsored by CME Outfitters, LLC
Supported by an educational grant from Lilly.
Specialty: Psychiatric Medicine
Release date: December 4, 2013
Valid through: December 4, 2014
Psychiatrists, primary care physicians, pharmacists, and other health care practitioners who manage patients with major depression.
After the initiation of antidepressant monotherapy, the importance of consistently and carefully monitoring patients with major depressive disorder (MDD) cannot be overemphasized. Most clinicians would agree that there is a clinical urgency to identify partial responders and nonresponders. Having a plan in place and clinical tools available helps optimize this process and forms the basis of timely, measurement-based care.
Compelling evidence indicates that residual symptoms at the end of a depressive episode, even if these symptoms are mild, are associated with significant psychosocial disability, an increased risk of relapse, and a more than three times increased speed of relapse return. Presence of residual symptoms may even be a stronger predictor of MDD recurrence than a history of multiple MDD episodes.
This educational activity will help clinicians improve monitoring of patients with MDD to identify cases that are treatment-resistant to monotherapy and to initiate the best, appropriate clinical plan to optimize pharmacotherapy toward a goal of preventing relapse.
All other healthcare professionals completing this course will be issued a statement of participation.